2Campagnoli C, Clavel-Chapelon F, Kaaks R, et al. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer [J]. J Steroid Biochem Mol Biol, 2005, 96(2) : 95 -108.
3Fournier A, Berrino F, Riboli E,et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort [J]. lnt J Cancer, 2005, 114(3) : 448 -454.
4Zakherah MS, Sayed GH, EI-Nashar SA,et al. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin [ J ]. Gynecol Obstet Invest ,2011,71 (4) : 281 - 284.
5Whitehead MI, Townsend PT, Gill DK,et al. Absorption and metabolism of oral progesterone [ J]. Br Med J, 1980,28 ( 10 ) :825 - 827.
6Stricker R, Eberhart R, Chevaitler M, et al. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer [ J]. Clin Chem Lab Med, 2006, 44(7) : 883 -887.
7Lenton EA, Lmldgren BM, Sexton L. Normal vatiation in the length of the luteal phase of the menstrual cycle: identification of the short luteal phase [J]. Br J Obstet Gynaecol, 1984, 91 (7) : 685 -689.
8Shangold MM, Tomai TP, Cook JD, et al. Factors associated with withdrawal bleeding ',after administration of oral micronized progesterone in women with secondary amenorrhea [ Jl. Fertil Steril, 1991, 56(6) : 1040 -1047.
